Tatsis Ourania 4

What Happened
Ourania Tatsis, EVP and Chief Regulatory & Quality Officer at Vertex Pharmaceuticals (VRTX), was issued two awards totaling 11,749 shares (7,866 + 3,883) on 2026-01-22. Both entries are reported as awards/acquisitions at $0.00 per share (total reported value $0), representing earned performance shares from previously granted performance stock unit awards. These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-01-22; reported on Form 4 filed 2026-01-26 (filed 4 days after the transaction — appears later than the typical 2-business-day Form 4 deadline).
• Award amounts: 7,866 shares (F1) and 3,883 shares (F2); total = 11,749 shares. Price reported: $0.00 per share.
• Shares owned after the transaction: not specified in the provided filing details.
• Footnote F1: Earned performance shares from a PSU grant dated 02/01/2023; committee certified attainment on 01/22/2026; shares will vest on 02/13/2026.
• Footnote F2: Earned performance shares from a PSU grant dated 02/12/2025; committee certified attainment on 01/22/2026; shares will vest in installments beginning 02/24/2026.
• Transaction code: A (award/grant/acquisition). No 10b5-1 plan, tax-withholding, or cashless exercise noted.

Context
Performance shares convert to actual stock only after certification of performance goals and any applicable vesting dates; they are compensation, not purchases or sales, and thus don’t directly signal buying/selling intent. The filing timing should be noted (filed several days after the transaction), which may be relevant to compliance review but does not change the nature of the award.